New data: new options for front-line therapy in NSCLC?
作者信息
Reinmuth Niels
机构信息
Thoracic Oncology, Asklepios Clinics Munich-Gauting, Gauting, Germany.
出版信息
ESMO Open. 2018 Apr 23;3(3):e000369. doi: 10.1136/esmoopen-2018-000369. eCollection 2018.
Abstract
摘要
相似文献
1
New data: new options for front-line therapy in NSCLC?
ESMO Open. 2018 Apr 23;3(3):e000369. doi: 10.1136/esmoopen-2018-000369. eCollection 2018.
2
Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Drugs R D. 2003;4(4):243-8. doi: 10.2165/00126839-200304040-00006.
3
Advances in the treatment of second-line non-small-cell lung cancer.
Lung Cancer. 2005 Oct;50 Suppl 1:S15-7. doi: 10.1016/s0169-5002(05)81554-5.
4
Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status.
Lung Cancer. 2010 Jul;69(1):110-5. doi: 10.1016/j.lungcan.2009.09.010. Epub 2009 Oct 24.
5
The safety of second-line treatment options for non-small cell lung cancer.
Expert Opin Drug Saf. 2017 Apr;16(4):471-479. doi: 10.1080/14740338.2017.1297795. Epub 2017 Mar 1.
6
Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
Thorac Cancer. 2019 Dec;10(12):2274-2281. doi: 10.1111/1759-7714.13221. Epub 2019 Oct 15.
7
Isoflurane Promotes Non-Small Cell Lung Cancer Malignancy by Activating the Akt-Mammalian Target of Rapamycin (mTOR) Signaling Pathway.
Med Sci Monit. 2016 Nov 29;22:4644-4650. doi: 10.12659/msm.898434.
8
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Clin Transl Oncol. 2018 Mar;20(3):366-373. doi: 10.1007/s12094-017-1723-1. Epub 2017 Aug 3.
9
Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.
Ann Transl Med. 2017 Sep;5(18):377. doi: 10.21037/atm.2017.07.18.
10
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors.
Expert Rev Anticancer Ther. 2018 Jan;18(1):71-80. doi: 10.1080/14737140.2018.1412260. Epub 2017 Dec 6.
引用本文的文献
1
Combination Treatment With Inhibitors of ERK and Autophagy Enhances Antitumor Activity of Betulinic Acid in Non-small-Cell Lung Cancer and .
Front Pharmacol. 2021 Jun 29;12:684243. doi: 10.3389/fphar.2021.684243. eCollection 2021.
2
lncRNA PCAT6 promotes non-small cell lung cancer cell proliferation, migration and invasion through regulating miR-330-5p.
Onco Targets Ther. 2018 Nov 1;11:7715-7724. doi: 10.2147/OTT.S178597. eCollection 2018.
本文引用的文献
1
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.
J Clin Oncol. 2018 Jun 10;36(17):1675-1684. doi: 10.1200/JCO.2017.77.0412. Epub 2018 Mar 23.
2
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Angiogenesis. 2017 May;20(2):185-204. doi: 10.1007/s10456-017-9552-y. Epub 2017 Mar 30.
3
Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.
Lancet Oncol. 2016 Nov;17(11):1497-1508. doi: 10.1016/S1470-2045(16)30498-3. Epub 2016 Oct 10.
4
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
N Engl J Med. 2016 Nov 10;375(19):1823-1833. doi: 10.1056/NEJMoa1606774. Epub 2016 Oct 8.
5
Statistical Challenges in the Design of Late-Stage Cancer Immunotherapy Studies.
Cancer Immunol Res. 2015 Dec;3(12):1292-8. doi: 10.1158/2326-6066.CIR-15-0260.
6
VEGF-targeted therapy: mechanisms of anti-tumour activity.
Nat Rev Cancer. 2008 Aug;8(8):579-91. doi: 10.1038/nrc2403. Epub 2008 Jul 3.
Zotero 插件